Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Precision BioSciences, Inc. (DTIL)
USD8.86
+0.28 (+3.22%)
US NASDAQ Healthcare Biotechnology
Address
302 East Pettigrew Street 27701
Durham, NC, US
Durham, NC, US
CEO
Juli Blanche
Website
precisionbiosciences.com
IPO
2019-03-28
CIK 1357874 ISIN US74019P2074
Description
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD8.86
+0.28 (+3.22%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
338.6K
Beta
1.28
Float Shares
9.85M
Free Float %
76.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.33% | +9.77% | +22.94% | +107.07% | +36.67% | +97.12% | +57.09% | -63.36% | -96.94% | -98.43% | -98.43% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (12 ratings, all time)
Buy
Price Targets & DCF
Current price
8.86
Low
19.00
+114.5%
Consensus
19.00
+114.5%
Median
19.00
+114.5%
High
19.00
+114.5%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
19.00
+114.5%
|
| Last Year | 1 |
19.00
+114.5%
|
| All Time | 3 |
16.67
+88.2%
|
Quality scores
Altman Z-Score
-4.05
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-50.1% Q1'26: +37,272.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-449.0% Q1'26: +37.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-220.7% Q1'26: -110.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-152.2% Q1'26: -83.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-953.2% Q1'26: -1,073.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+86.3% Q1'26: +43.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.58× Q1'26: -0.84× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
22.24M
est: 22.71M (-2.1%)
|
24.29M
est: 21.26M (+14.2%)
|
115.53M
est: 116.73M (-1.0%)
|
25.10M
est: 21.58M (+16.3%)
|
48.73M
est: 87.64M (-44.4%)
|
68.70M
est: 72.30M (-5.0%)
|
34.26M
est: 9.14M (+274.9%)
|
20.48M
16.02M – 24.39M
+124.1% YoY
|
15.25M
11.92M – 18.16M
-25.6% YoY
|
15.73M
12.30M – 18.73M
+3.1% YoY
|
24.25M
18.96M – 28.87M
+54.2% YoY
|
110.82M
86.65M – 131.96M
+357.0% YoY
|
| EBITDA |
-87.38M
est: -11.97M (-629.8%)
|
-99.19M
est: -11.21M (-784.9%)
|
-20.27M
est: -61.54M (+67.1%)
|
-62.79M
est: -11.38M (-451.9%)
|
-32.04M
est: -46.21M (+30.7%)
|
13.53M
est: -38.12M (+135.5%)
|
-49.40M
est: -4.82M (-925.0%)
|
-10.80M
-12.86M – -8.45M
-124.1% YoY
|
-8.04M
-9.57M – -6.29M
+25.6% YoY
|
-8.29M
-9.87M – -6.48M
-3.1% YoY
|
-12.78M
-15.22M – -10.00M
-54.2% YoY
|
-58.43M
-69.57M – -45.69M
-357.0% YoY
|
| EBIT |
-92.70M
est: -13.45M (-589.4%)
|
-109.01M
est: -12.59M (-765.9%)
|
-30.47M
est: -69.11M (+55.9%)
|
-71.80M
est: -12.78M (-461.9%)
|
-40.30M
est: -51.89M (+22.3%)
|
8.95M
est: -42.81M (+120.9%)
|
-52.15M
est: -5.41M (-863.6%)
|
-12.13M
-14.44M – -9.48M
-124.1% YoY
|
-9.03M
-10.75M – -7.06M
+25.6% YoY
|
-9.31M
-11.09M – -7.28M
-3.1% YoY
|
-14.36M
-17.10M – -11.23M
-54.2% YoY
|
-65.61M
-78.13M – -51.31M
-357.0% YoY
|
| Net Income |
-92.88M
est: -466.21M (+80.1%)
|
-109.01M
est: -450.80M (+75.8%)
|
-30.60M
est: -129.68M (+76.4%)
|
-111.64M
est: -254.15M (+56.1%)
|
-61.32M
est: 40.04M (-253.2%)
|
7.17M
est: 850.4K (+742.8%)
|
-46.61M
est: -77.29M (+39.7%)
|
-33.04M
-41.98M – -24.10M
+57.3% YoY
|
-30.52M
-38.78M – -22.26M
+7.6% YoY
|
-32.02M
-40.18M – -23.86M
-4.9% YoY
|
-30.78M
-38.42M – -22.06M
+3.9% YoY
|
-9.23M
-11.53M – -6.62M
+70.0% YoY
|
| SGA |
27.03M
est: 21.75M (+24.3%)
|
36.05M
est: 20.36M (+77.0%)
|
39.67M
est: 111.80M (-64.5%)
|
41.28M
est: 20.67M (+99.7%)
|
39.09M
est: 74.41M (-47.5%)
|
35.30M
est: 61.39M (-42.5%)
|
32.24M
est: 7.76M (+315.4%)
|
17.39M
13.60M – 20.71M
+124.1% YoY
|
12.95M
10.12M – 15.42M
-25.6% YoY
|
13.35M
10.44M – 15.90M
+3.1% YoY
|
20.59M
16.10M – 24.51M
+54.2% YoY
|
94.09M
73.57M – 112.04M
+357.0% YoY
|
| EPS |
-59.50
est: -67.73 (+12.1%)
|
-62.85
est: -65.49 (+4.0%)
|
-15.60
est: -18.84 (+17.2%)
|
-38.10
est: -35.73 (-6.6%)
|
-15.96
est: 3.18 (-602.3%)
|
1.05
est: 0.07 (+1,455.6%)
|
-3.63
est: -6.14 (+40.8%)
|
-2.62
-3.27 – -1.88
+57.3% YoY
|
-2.42
-3.02 – -1.74
+7.6% YoY
|
-2.42
-3.13 – -1.86
+0.2% YoY
|
-2.40
-3.00 – -1.72
+0.7% YoY
|
-0.72
-0.90 – -0.52
+70.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-61.58M
OE per share TTM
-5.19
Owner's Yield
-58.55%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
46.1%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
8
Total invested
12.90M
Insider transactions (90d)
0
Beneficial owners (>5%)
25
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Novartis AG | 12.41M | 16.60% | — | 12.41M | — | 12.41M | HC, CO | Switzerland | 2022-06-27 | ↗ |
| 2 | Novartis Pharma AG | 12.41M | 16.60% | — | 12.41M | — | 12.41M | CO | Switzerland | 2022-06-27 | ↗ |
| 3 | Dr. Jeffrey R. Jay, M.D. | 8.10M | 7.30% | — | 8.10M | — | — | HC, IN | USA | 2023-02-27 | ↗ |
| 4 | Great Point Partners, LLC | 8.10M | 7.30% | — | 8.10M | — | — | IA, OO | Delaware | 2023-02-27 | ↗ |
| 5 | Mr. Ortav Yehudai | 8.10M | 7.30% | — | 8.10M | — | — | HC, IN | Delaware | 2023-02-27 | ↗ |
| 6 | Tang Capital Management, LLC | 6.40M | 5.20% | — | 6.40M | — | 6.40M | OO | DELAWARE | 2024-02-05 | ↗ |
| 7 | Derek Jantz | 4.29M | 3.90% | 4.29M | — | 4.29M | 4.29M | IN | U.S. | 2022-08-31 | ↗ |
| 8 | Capital World Investors ** | 4.06M | 7.90% | 4.06M | — | 4.06M | — | IA | Delaware | 2020-02-14 | ↗ |
| 9 | Eli Lilly and Company | 3.76M | 7.17% | 3.76M | — | 3.76M | — | CO | Indiana | 2021-01-08 | ↗ |
| 10 | Corey Goodman | 3.74M | 7.20% | — | 3.74M | — | 3.74M | IN | — | 2020-06-08 | ↗ |
| 11 | Robert Adelman | 3.74M | 7.20% | — | 3.74M | — | 3.74M | IN | — | 2020-06-08 | ↗ |
| 12 | venBio Global Strategic Fund, L.P. | 3.74M | 7.20% | — | 3.74M | — | 3.74M | PN | — | 2020-06-08 | ↗ |
| 13 | venBio Global Strategic GP, L.P. | 3.74M | 7.20% | — | 3.74M | — | 3.74M | PN | — | 2020-06-08 | ↗ |
| 14 | The Vanguard Group - 23-1945930 | 3.24M | 5.34% | — | 93.1K | — | — | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 15 | (1) BlackRock, Inc. | 2.38M | 2.40% | 2.29M | — | 2.38M | — | HC | Delaware | 2022-07-08 | ↗ |
| 16 | Aquilo Capital Management, LLC | 662.7K | 9.90% | — | 662.7K | — | — | IA, HC, OO | Delaware | 2024-03-18 | ↗ |
| 17 | Marc Schneidman | 662.7K | 9.90% | — | 662.7K | — | — | HC, IN | United States | 2024-03-18 | ↗ |
| 18 | 00-0000000 | 511.1K | 8.00% | — | 511.1K | — | 511.1K | CO | Cayman Islands | 2024-03-11 | ↗ |
| 19 | EIN #00-0000000 | 511.1K | 8.00% | — | 511.1K | — | 511.1K | IA, HC | Jersey, Channel Islands | 2024-03-11 | ↗ |
| 20 | Joseph Edelman | 500.0K | 7.90% | — | 500.0K | — | 500.0K | IN | Delaware | 2024-03-14 | ↗ |
| 21 | Perceptive Advisors LLC | 500.0K | 7.90% | — | 500.0K | — | 500.0K | IA | Delaware | 2024-03-14 | ↗ |
| 22 | Perceptive Life Sciences Master Fund, Ltd. | 500.0K | 7.90% | — | 500.0K | — | 500.0K | CO | Delaware | 2024-03-14 | ↗ |
| 23 | Aquilo Capital, L.P. | 466.8K | 7.10% | — | 466.8K | — | — | PN | Delaware | 2024-03-18 | ↗ |
| 24 | Highbridge Capital Management, LLC | 406.3K | 5.30% | — | 406.3K | — | — | IA, OO | State of Delaware | 2024-11-14 | ↗ |
| 25 | 95-1411037 | 13.00 | 7.00% | 4.27M | — | 4.27M | — | IA | Delaware | 2022-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
8
-59 vs prev Q
New positions
1
Closed positions
60
Increased
4
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | EMPERY ASSET MANAGEMENT, LP | 2.19M +2.2M (+100.0%) | 9.13B +9.1B (+100.0%) | 18.57% +18.570 pp | 8.05% +8.051 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 2 | ABRDN PLC | 2.14M +2.1M (+100.0%) | 8.90M +8.9M (+100.0%) | 18.10% +18.096 pp | 0.01% +0.014 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 3 | OCTAGON CAPITAL ADVISORS LP | 1.92M +1.9M (+100.0%) | 7.98M +8.0M (+100.0%) | 16.23% +16.229 pp | 0.97% +0.969 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 4 | BLEICHROEDER LP | 1.66M +587.5K (+54.7%) | 6.92M +982.0K (+16.5%) | 14.07% +4.336 pp | 1.22% +0.060 pp | USD4.19 -0.7% | 4 qtrs — |
| 5 | BOOTHBAY FUND MANAGEMENT, LLC | 1.07M +887.5K (+497.1%) | 4.43M +3.4M (+350.0%) | 9.02% +7.404 pp | 0.07% +0.052 pp | USD4.26 -2.3% | 4 qtrs — |
| 6 | — | 1.0K +1.0K (+100.0%) | 4.16M +4.2M (+100.0%) | 0.01% +0.009 pp | 0.00% +0.004 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 7 | LYNX1 CAPITAL MANAGEMENT LP | 993.9K -48.7K (-4.7%) | 4.13M -1.6M (-28.2%) | 8.41% -1.028 pp | 0.84% -0.334 pp | USD3.92 +6.1% | 5 qtrs — |
| 8 | VANGUARD GROUP INC | 906.8K +414.2K (+84.1%) | 3.77M +1.1M (+38.7%) | 7.67% +3.214 pp | 0.00% +0.000 pp | USD7.53 -44.8% | 8 qtrs — |
| 9 | ALYESKA INVESTMENT GROUP, L.P. | 798.0K +798.0K (+100.0%) | 3.32M +3.3M (+100.0%) | 6.75% +6.752 pp | 0.01% +0.009 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 10 | DRIEHAUS CAPITAL MANAGEMENT LLC | 787.7K +787.7K (+100.0%) | 3.28M +3.3M (+100.0%) | 6.67% +6.665 pp | 0.02% +0.022 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 11 | SPHERA FUNDS MANAGEMENT LTD. | 396.1K +396.1K (+100.0%) | 1.65M +1.6M (+100.0%) | 3.35% +3.352 pp | 0.32% +0.319 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 12 | RENAISSANCE TECHNOLOGIES LLC | 326.5K +130.3K (+66.4%) | 1.36M +275.2K (+25.4%) | 2.76% +0.987 pp | 0.00% +0.001 pp | USD6.64 -37.3% | 8 qtrs — |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 225.7K +116.1K (+106.0%) | 938.8K +334.2K (+55.3%) | 1.91% +0.918 pp | 0.00% +0.000 pp | USD6.65 -37.4% | 8 qtrs — |
| 14 | BLACKROCK, INC. | 168.3K +69.6K (+70.5%) | 700.3K +155.4K (+28.5%) | 1.42% +0.531 pp | 0.00% +0.000 pp | USD6.06 -31.4% | 6 qtrs — |
| 15 | TWO SIGMA INVESTMENTS, LP | 139.5K +56.4K (+67.9%) | 580.4K +121.8K (+26.6%) | 1.18% +0.428 pp | 0.00% +0.000 pp | USD4.87 -14.6% | 4 qtrs — |
| 16 | MORGAN STANLEY | 99.8K +89.3K (+852.9%) | 415.2K +357.4K (+618.1%) | 0.84% +0.750 pp | 0.00% +0.000 pp | USD4.89 -14.9% | 8 qtrs — |
| 17 | 683 CAPITAL MANAGEMENT, LLC | 97.1K +97.1K (+100.0%) | 403.9K +403.9K (+100.0%) | 0.82% +0.822 pp | 0.02% +0.018 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 18 | COMMONWEALTH EQUITY SERVICES, LLC | 93.3K +37.5K (+67.1%) | 388.2K +80.2K (+26.0%) | 0.79% +0.284 pp | 0.00% +0.000 pp | USD4.31 -3.5% | 5 qtrs — |
| 19 | NORTHERN TRUST CORP | 86.5K +48.4K (+127.1%) | 359.7K +149.6K (+71.2%) | 0.73% +0.387 pp | 0.00% +0.000 pp | USD6.12 -32.0% | 7 qtrs — |
| 20 | TWO SIGMA ADVISERS, LP | 83.4K +31.4K (+60.4%) | 347.1K +60.0K (+20.9%) | 0.71% +0.235 pp | 0.00% +0.000 pp | USD5.01 -17.0% | 2 qtrs — |
| 21 | MARSHALL WACE, LLP | 70.9K +70.9K (+100.0%) | 295.0K +295.0K (+100.0%) | 0.60% +0.600 pp | 0.00% +0.000 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 22 | QUARRY LP | 68.3K +8.9K (+15.1%) | 284.2K -43.6K (-13.3%) | 0.58% +0.041 pp | 0.04% -0.027 pp | USD4.19 -0.7% | 3 qtrs — |
| 23 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 66.6K +66.6K (+100.0%) | 277.0K +277.0K (+100.0%) | 0.56% +0.563 pp | 0.00% +0.000 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 24 | QUADRATURE CAPITAL LTD | 62.1K +48.2K (+344.7%) | 258.5K +181.3K (+235.1%) | 0.53% +0.399 pp | 0.00% +0.002 pp | USD4.47 -6.9% | 2 qtrs — |
| 25 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 61.9K +— (+0.0%) | 257.5K -84.2K (-24.6%) | 0.52% -0.037 pp | 0.01% -0.002 pp | USD4.20 -1.0% | 3 qtrs — |
| 26 | UBS GROUP AG | 61.3K +36.9K (+150.6%) | 255.1K +120.0K (+88.8%) | 0.52% +0.297 pp | 0.00% +0.000 pp | USD4.08 +2.0% | 8 qtrs — |
| 27 | OMERS ADMINISTRATION CORP | 60.7K +60.7K (+100.0%) | 252.5K +252.5K (+100.0%) | 0.51% +0.514 pp | 0.00% +0.002 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 28 | STATE STREET CORP | 59.0K +20.9K (+54.8%) | 245.6K +35.1K (+16.7%) | 0.50% +0.154 pp | 0.00% +0.000 pp | USD5.46 -23.8% | 7 qtrs — |
| 29 | ACADIAN ASSET MANAGEMENT LLC | 56.3K -63.0K (-52.8%) | 233.0K -425.0K (-64.6%) | 0.48% -0.604 pp | 0.00% -0.001 pp | USD9.78 -57.5% | 8 qtrs — |
| 30 | TREXQUANT INVESTMENT LP | 40.3K +40.3K (+100.0%) | 167.5K +167.5K (+100.0%) | 0.34% +0.341 pp | 0.00% +0.002 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 31 | GSA CAPITAL PARTNERS LLP | 38.8K +21.0K (+118.8%) | 161.0K +63.0K (+64.3%) | 0.33% +0.168 pp | 0.01% +0.006 pp | USD4.78 -13.0% | 2 qtrs — |
| 32 | XTX TOPCO LTD | 35.9K +35.9K (+100.0%) | 149.5K +149.5K (+100.0%) | 0.30% +0.304 pp | 0.00% +0.004 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 33 | JUMP FINANCIAL, LLC | 35.8K +35.8K (+100.0%) | 148.9K +148.9K (+100.0%) | 0.30% +0.303 pp | 0.00% +0.002 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 34 | POINT72 ASSET MANAGEMENT, L.P. | 29.6K +29.6K (+100.0%) | 123.2K +123.2K (+100.0%) | 0.25% +0.251 pp | 0.00% +0.000 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 35 | DIMENSIONAL FUND ADVISORS LP | 23.8K -19.9K (-45.6%) | 98.8K -142.1K (-59.0%) | 0.20% -0.194 pp | 0.00% +0.000 pp | USD3.81 +9.2% | 5 qtrs — |
| 36 | VELAN CAPITAL INVESTMENT MANAGEMENT LP | 20.0K +— (+0.0%) | 83.2K -27.2K (-24.6%) | 0.17% -0.012 pp | 0.05% -0.055 pp | USD5.52 -24.6% | 2 qtrs — |
| 37 | CITADEL ADVISORS LLC | 15.7K -6.4K (-28.9%) | 65.5K -56.7K (-46.4%) | 0.13% -0.067 pp | 0.00% +0.000 pp | USD5.52 -24.6% | 2 qtrs — |
| 38 | MILLER FINANCIAL SERVICES LLC | 15.0K +5.0K (+50.0%) | 62.4K +7.2K (+13.0%) | 0.13% +0.036 pp | 0.07% +0.009 pp | USD4.57 -9.0% | 4 qtrs — |
| 39 | LPL FINANCIAL LLC | 14.0K +2.0K (+16.6%) | 58.4K -8.1K (-12.1%) | 0.12% +0.010 pp | 0.00% +0.000 pp | USD4.19 -0.7% | 3 qtrs — |
| 40 | OCCUDO QUANTITATIVE STRATEGIES LP | 12.6K +12.6K (+100.0%) | 52.3K +52.3K (+100.0%) | 0.11% +0.106 pp | 0.00% +0.004 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 41 | ENGINEERS GATE MANAGER LP | 10.4K +10.4K (+100.0%) | 43.1K +43.1K (+100.0%) | 0.09% +0.088 pp | 0.00% +0.001 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 42 | BANK OF AMERICA CORP /DE/ | 10.2K +10.0K (+4,872.8%) | 42.6K +41.5K (+3,644.7%) | 0.09% +0.085 pp | 0.00% +0.000 pp | USD4.31 -3.5% | 8 qtrs — |
| 43 | CI PRIVATE WEALTH, LLC | 10.0K +— (+0.0%) | 41.6K -13.6K (-24.6%) | 0.08% -0.006 pp | 0.00% +0.000 pp | USD4.20 -1.0% | 8 qtrs — |
| 44 | HBK SORCE ADVISORY LLC | 10.0K +10.0K (+100.0%) | 38.1K +38.1K (+100.0%) | 0.08% +0.085 pp | 0.00% +0.001 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 45 | BARCLAYS PLC | 5.2K +2.3K (+81.6%) | 21.7K -4.0K (-15.7%) | 0.04% +0.018 pp | 0.00% +0.000 pp | USD5.63 -26.1% | 8 qtrs — |
| 46 | ALLWORTH FINANCIAL LP | 4.8K +— (+0.0%) | 19.8K -6.5K (-24.6%) | 0.04% -0.003 pp | 0.00% +0.000 pp | USD15.37 -72.9% | 8 qtrs — |
| 47 | VIVO CAPITAL, LLC | 4.7K +— (+0.0%) | 19.4K -6.4K (-24.6%) | 0.04% -0.003 pp | 0.00% -0.001 pp | USD15.37 -72.9% | 8 qtrs — |
| 48 | SIMPLEX TRADING, LLC | 3.4K +3.4K (+100.0%) | 14.2K +14.2K (+100.0%) | 0.03% +0.029 pp | 0.00% +0.000 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 49 | NEWBRIDGE FINANCIAL SERVICES GROUP, INC. | 1.6K +— (+0.0%) | 6.7K -2.2K (-24.6%) | 0.01% -0.001 pp | 0.00% 0.000 pp | USD3.81 +9.2% | 5 qtrs — |
| 50 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 1.0K +— (+0.0%) | 4.2K -1.4K (-24.6%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD5.52 -24.6% | 2 qtrs — |
| 51 | CWM, LLC | 1.0K +— (+0.0%) | 4.0K -2.0K (-33.3%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD3.81 +9.2% | 5 qtrs — |
| 52 | ROYAL BANK OF CANADA | 527.00 +527.0 (+100.0%) | 2.0K +2.0K (+100.0%) | 0.00% +0.005 pp | 0.00% +0.000 pp | USD4.16 +0.0% | 6 qtrs — |
| 53 | SBI SECURITIES CO., LTD. | 468.00 -338.0 (-41.9%) | 1.9K -2.5K (-56.2%) | 0.00% -0.003 pp | 0.00% 0.000 pp | USD4.55 -8.6% | 5 qtrs — |
| 54 | RHUMBLINE ADVISERS | 275.00 +— (+0.0%) | 1.1K -374.0 (-24.6%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD8.96 -53.6% | 6 qtrs — |
| 55 | SOUTHSTATE CORP | 95.00 +— (+0.0%) | 395.00 -129.0 (-24.6%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD9.88 -57.9% | 7 qtrs — |
| 56 | ADVISOR GROUP HOLDINGS, INC. | 91.00 +— (+0.0%) | 378.00 -113.0 (-23.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD4.43 -6.1% | 8 qtrs — |
| 57 | BNP PARIBAS ARBITRAGE, SNC | 82.00 +— (+0.0%) | 341.00 -112.0 (-24.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD11.68 -64.4% | 8 qtrs — |
| 58 | WELLS FARGO & COMPANY/MN | 35.00 +— (+0.0%) | 146.00 -47.0 (-24.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD9.91 -58.0% | 8 qtrs — |
| 59 | NEWEDGE ADVISORS, LLC | 22.00 +— (+0.0%) | 90.00 -30.0 (-25.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD15.32 -72.8% | 8 qtrs — |
| 60 | JONES FINANCIAL COMPANIES LLLP | 13.00 -127.0 (-90.7%) | 54.00 -654.0 (-92.4%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD4.85 -14.2% | 3 qtrs — |
| 61 | FEDERATION DES CAISSES DESJARDINS DU QUEBEC | 12.00 +— (+0.0%) | 50.00 -16.0 (-24.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD15.33 -72.9% | 8 qtrs — |
| 62 | FARTHER FINANCE ADVISORS, LLC | 10.00 +10.0 (+100.0%) | 42.00 +42.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.10 +1.5% | 1 qtrs NEW |
| 63 | JPMORGAN CHASE & CO | 8.00 +— (+0.0%) | 33.00 -11.0 (-25.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD15.25 -72.7% | 8 qtrs — |
| 64 | INVESTORS RESEARCH CORP | 8.00 +— (+0.0%) | 33.00 -11.0 (-25.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD15.25 -72.7% | 8 qtrs — |
| 65 | MAI CAPITAL MANAGEMENT | 7.00 +— (+0.0%) | 30.00 -9.0 (-23.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.71 +12.1% | 5 qtrs — |
| 66 | HARBOUR INVESTMENTS, INC. | 3.00 +— (+0.0%) | 12.00 -5.0 (-29.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD9.67 -57.0% | 7 qtrs — |
| 67 | AVION WEALTH | — -203.0 (-100.0%) | — -1.0K (-100.0%) | 0.00% -0.002 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 68 | PHYSICIAN WEALTH ADVISORS, INC. | — -196.0 (-100.0%) | — -1.1K (-100.0%) | 0.00% -0.002 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 69 | TANG CAPITAL MANAGEMENT LLC | — -653.6K (-100.0%) | — -3.6M (-100.0%) | 0.00% -5.917 pp | 0.00% -0.139 pp | USD— | 8 qtrs SOLD |
| 70 | TEJARA CAPITAL LTD | — -58.8K (-100.0%) | — -324.3K (-100.0%) | 0.00% -0.532 pp | 0.00% -0.169 pp | USD— | 8 qtrs SOLD |
| 71 | NATIONAL BANK OF CANADA /FI/ | — -7.6K (-100.0%) | — -41.4K (-100.0%) | 0.00% -0.069 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 72 | RISE ADVISORS, LLC | — -206.0 (-100.0%) | — -1.1K (-100.0%) | 0.00% -0.002 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 73 | VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | — -13.1K (-100.0%) | — -72.5K (-100.0%) | 0.00% -0.119 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 74 | VIRTU FINANCIAL LLC | — -15.2K (-100.0%) | — -84.0K (-100.0%) | 0.00% -0.137 pp | 0.00% -0.005 pp | USD— | 2 qtrs SOLD |
| 75 | ZURCHER KANTONALBANK (ZURICH CANTONALBANK) | — -69.0 (-100.0%) | — -381.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 42 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.63% | 137.9K | 0.20% |
| 2 | iShares Micro-Cap ETF IWC | 0.05% | 705.7K | 0.60% |
| 3 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.03% | 296.8K | 0.20% |
| 4 | iShares Russell 2000 Value ETF IWN | 0.01% | 1.91M | 0.24% |
| 5 | Fidelity Enhanced Small Cap ETF FESM | 0.01% | 520.2K | 0.28% |
| 6 | Global X - Russell 2000 ETF RSSL | 0.01% | 98.3K | 0.08% |
| 7 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.01% | 21.2K | 0.25% |
| 8 | iShares Russell 2000 BuyWrite ETF IWMW | 0.01% | 3.4K | 0.39% |
| 9 | iShares Russell 2000 ETF IWM | 0.01% | 5.02M | 0.19% |
| 10 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.01% | 172.5K | 0.30% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.67
Neutral
Ratio by volume
0.76
Neutral
Buys
16
Sells
24
Shares acquired
342.9K
Shares disposed
450.6K
Cash buys
—
Cash sales
8.00
Net activity
-107,624
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-18 | Scimeca Dario | Officer | S-Sale | D | Common Stock | 4,925 | 3.84 | 18.9K | 56,457 | D | ↗ |
| 2026-02-18 | SMITH J. JEFFERSON | Officer | S-Sale | D | Common Stock | 4,925 | 3.84 | 18.9K | 121,926 | D | ↗ |
| 2026-02-18 | Kelly John Alexander | Officer | S-Sale | D | Common Stock | 8,149 | 3.84 | 31.3K | 125,883 | D | ↗ |
| 2026-02-18 | Amoroso Michael | Director / Officer | S-Sale | D | Common Stock | 20,559 | 3.84 | 78.9K | 243,392 | D | ↗ |
| 2026-02-17 | Scimeca Dario | Officer | M-Exempt | A | Common Stock | 16,667 | 0.00 | — | 61,382 | D | ↗ |
| 2026-02-17 | SMITH J. JEFFERSON | Officer | M-Exempt | A | Common Stock | 16,667 | 0.00 | — | 126,851 | D | ↗ |
| 2026-02-17 | Kelly John Alexander | Officer | M-Exempt | A | Common Stock | 27,584 | 0.00 | — | 134,032 | D | ↗ |
| 2026-02-17 | Amoroso Michael | Director / Officer | M-Exempt | A | Common Stock | 67,797 | 0.00 | — | 263,951 | D | ↗ |
| 2026-01-22 | Amoroso Michael | Director / Officer | S-Sale | D | Common Stock | 34,799 | 4.17 | 145.1K | 196,154 | D | ↗ |
| 2026-01-21 | Scimeca Dario | Officer | S-Sale | D | Common Stock | 8,854 | 4.03 | 35.7K | 44,715 | D | ↗ |
| 2026-01-21 | SMITH J. JEFFERSON | Officer | S-Sale | D | Common Stock | 10,200 | 4.03 | 41.1K | 110,184 | D | ↗ |
| 2026-01-21 | Kelly John Alexander | Officer | S-Sale | D | Common Stock | 15,213 | 4.03 | 61.3K | 106,448 | D | ↗ |
| 2026-01-20 | Scimeca Dario | Officer | M-Exempt | D | Restricted Stock Units | 1,978 | 0.00 | — | 0 | D | ↗ |
| 2026-01-20 | SMITH J. JEFFERSON | Officer | M-Exempt | A | Common Stock | 2,500 | 0.00 | — | 93,718 | D | ↗ |
| 2026-01-20 | Kelly John Alexander | Officer | M-Exempt | A | Common Stock | 26,575 | 0.00 | — | 121,661 | D | ↗ |
| 2026-01-20 | Amoroso Michael | Director / Officer | M-Exempt | D | Restricted Stock Units | 8,888 | 0.00 | — | 0 | D | ↗ |
| 2025-12-16 | Germano Geno J | Director | P-Purchase | A | Common Stock | 3,000 | 4.72 | 14.2K | 23,883 | D | ↗ |
| 2025-12-16 | Frankel Stanley | Director | P-Purchase | A | Common Stock | 2,700 | 4.70 | 12.7K | 19,478 | D | ↗ |
| 2025-12-15 | Brown Melinda | Director | P-Purchase | A | Common Stock | 1,381 | 4.97 | 6.9K | 23,346 | D | ↗ |
| 2025-11-03 | Scimeca Dario | Officer | S-Sale | D | Common Stock | 665 | 6.49 | 4.3K | 28,258 | D | ↗ |
| 2025-11-03 | Kelly John Alexander | Officer | S-Sale | D | Common Stock | 1,303 | 6.49 | 8.5K | 77,298 | D | ↗ |
| 2025-11-03 | Amoroso Michael | Director / Officer | M-Exempt | D | Restricted Stock Units | 9,444 | 0.00 | — | 0 | D | ↗ |
| 2025-11-02 | Scimeca Dario | Officer | M-Exempt | D | Restricted Stock Units | 1,835 | 0.00 | — | 0 | D | ↗ |
| 2025-11-02 | Kelly John Alexander | Officer | M-Exempt | D | Restricted Stock Units | 3,605 | 0.00 | — | 0 | D | ↗ |
| 2025-11-02 | Amoroso Michael | Director / Officer | M-Exempt | A | Common Stock | 9,444 | 0.00 | — | 118,984 | D | ↗ |
| 2025-09-26 | Frankel Stanley | Director | P-Purchase | A | Common Stock | 2,700 | 4.97 | 13.4K | 16,778 | D | ↗ |
| 2025-09-22 | Brown Melinda | Director | P-Purchase | A | Common Stock | 1,400 | 4.89 | 6.8K | 21,965 | D | ↗ |
| 2025-07-03 | Kelly John Alexander | Officer | S-Sale | D | Common Stock | 14,827 | 4.26 | 63.2K | 73,485 | D | ↗ |
| 2025-06-25 | Buehler Kevin | Director | P-Purchase | A | Common Stock | 5,076 | 4.16 | 21.1K | 28,137 | D | ↗ |
| 2025-06-25 | Brown Melinda | Director | P-Purchase | A | Common Stock | 1,682 | 4.14 | 7.0K | 20,565 | D | ↗ |
| 2025-06-03 | Pire Shari Lisa | Director | A-Award | A | Restricted Stock Units | 21,000 | 0.00 | — | 21,000 | D | ↗ |
| 2025-06-03 | Germano Geno J | Director | A-Award | A | Restricted Stock Units | 21,000 | 0.00 | — | 21,000 | D | ↗ |
| 2025-06-03 | Frankel Stanley | Director | A-Award | A | Restricted Stock Units | 21,000 | 0.00 | — | 21,000 | D | ↗ |
| 2025-06-03 | Buehler Kevin | Director | A-Award | A | Restricted Stock Units | 21,000 | 0.00 | — | 21,000 | D | ↗ |
| 2025-06-03 | Brown Melinda | Director | A-Award | A | Restricted Stock Units | 21,000 | 0.00 | — | 21,000 | D | ↗ |
| 2025-06-02 | Scimeca Dario | Officer | A-Award | A | Restricted Stock Units | 50,000 | 0.00 | — | 50,000 | D | ↗ |
| 2025-06-02 | SMITH J. JEFFERSON | Officer | A-Award | A | Restricted Stock Units | 50,000 | 0.00 | — | 50,000 | D | ↗ |
| 2025-06-02 | Kelly John Alexander | Officer | A-Award | A | Restricted Stock Units | 82,750 | 0.00 | — | 82,750 | D | ↗ |
| 2025-06-02 | Amoroso Michael | Director / Officer | A-Award | A | Restricted Stock Units | 203,390 | 0.00 | — | 203,390 | D | ↗ |
| 2025-05-27 | Pire Shari Lisa | Director | M-Exempt | A | Common Stock | 9,826 | 0.00 | — | 14,028 | D | ↗ |
| 2025-05-27 | Germano Geno J | Director | M-Exempt | D | Restricted Stock Units | 9,826 | 0.00 | — | 0 | D | ↗ |
| 2025-05-27 | Frankel Stanley | Director | M-Exempt | D | Restricted Stock Units | 9,826 | 0.00 | — | 0 | D | ↗ |
| 2025-05-27 | Buehler Kevin | Director | M-Exempt | A | Common Stock | 9,826 | 0.00 | — | 23,061 | D | ↗ |
| 2025-05-27 | Brown Melinda | Director | M-Exempt | D | Restricted Stock Units | 9,826 | 0.00 | — | 0 | D | ↗ |
| 2025-03-26 | Buehler Kevin | Director | P-Purchase | A | Common Stock | 4,523 | 4.67 | 21.1K | 13,235 | D | ↗ |
| 2025-03-26 | Brown Melinda | Director | P-Purchase | A | Common Stock | 1,839 | 4.75 | 8.7K | 9,057 | D | ↗ |
| 2025-03-25 | Germano Geno J | Director | P-Purchase | A | Common Stock | 3,250 | 5.30 | 17.2K | 11,057 | D | ↗ |
| 2025-03-24 | Amoroso Michael | Director / Officer | S-Sale | D | Common Stock | 964 | 5.56 | 5.4K | 109,540 | D | ↗ |
| 2025-03-21 | Amoroso Michael | Director / Officer | M-Exempt | A | Common Stock | 3,417 | 0.00 | — | 110,504 | D | ↗ |
| 2025-03-04 | Scimeca Dario | Officer | S-Sale | D | Common Stock | 272 | 4.91 | 1.3K | 25,000 | D | ↗ |
| 2025-03-04 | SMITH J. JEFFERSON | Officer | S-Sale | D | Common Stock | 154 | 4.91 | 756.14 | 87,805 | D | ↗ |
| 2025-03-03 | Scimeca Dario | Officer | M-Exempt | D | Restricted Stock Units | 919 | 0.00 | — | 0 | D | ↗ |
| 2025-03-03 | SMITH J. JEFFERSON | Officer | M-Exempt | A | Common Stock | 519 | 0.00 | — | 87,959 | D | ↗ |
| 2025-03-03 | Kelly John Alexander | Officer | M-Exempt | D | Restricted Stock Units | 1,702 | 0.00 | — | 0 | D | ↗ |
| 2025-01-22 | Scimeca Dario | Officer | S-Sale | D | Common Stock | 8,928 | 4.79 | 42.8K | 24,353 | D | ↗ |
| 2025-01-22 | SMITH J. JEFFERSON | Officer | S-Sale | D | Common Stock | 10,287 | 4.79 | 49.3K | 87,440 | D | ↗ |
| 2025-01-21 | Amoroso Michael | Director / Officer | S-Sale | D | Common Stock | 36,838 | 4.67 | 172.0K | 107,087 | D | ↗ |
| 2025-01-20 | Scimeca Dario | Officer | M-Exempt | D | Restricted Stock Units | 8,427 | 0.00 | — | 16,850 | D | ↗ |
| 2025-01-20 | SMITH J. JEFFERSON | Officer | M-Exempt | D | Restricted Stock Units | 2,500 | 0.00 | — | 2,500 | D | ↗ |
| 2025-01-20 | Kelly John Alexander | Officer | M-Exempt | D | Restricted Stock Units | 3,889 | 0.00 | — | 3,888 | D | ↗ |
| 2025-01-20 | Amoroso Michael | Director / Officer | M-Exempt | A | Common Stock | 115,388 | 0.00 | — | 143,925 | D | ↗ |
| 2024-12-30 | Germano Geno J | Director | P-Purchase | A | Common Stock | 3,605 | 4.49 | 16.2K | 7,807 | D | ↗ |
| 2024-12-27 | Kelly John Alexander | Officer | P-Purchase | A | Common Stock | 2,113 | 4.75 | 10.0K | 40,186 | D | ↗ |
| 2024-12-27 | Buehler Kevin | Director | P-Purchase | A | Common Stock | 4,320 | 4.88 | 21.1K | 8,712 | D | ↗ |
| 2024-12-26 | Brown Melinda | Director | P-Purchase | A | Common Stock | 3,016 | 4.55 | 13.7K | 7,218 | D | ↗ |
| 2024-11-21 | Kelly John Alexander | Officer | P-Purchase | A | Common Stock | 3,000 | 6.76 | 20.3K | 38,073 | D | ↗ |
| 2024-11-04 | Scimeca Dario | Officer | S-Sale | D | Common Stock | 588 | 8.19 | 4.8K | 7,969 | D | ↗ |
| 2024-11-04 | Amoroso Michael | Director / Officer | S-Sale | D | Common Stock | 3,012 | 8.19 | 24.7K | 28,537 | D | ↗ |
| 2024-11-02 | Scimeca Dario | Officer | M-Exempt | A | Common Stock | 1,836 | 0.00 | — | 8,557 | D | ↗ |
| 2024-11-02 | Kelly John Alexander | Officer | M-Exempt | D | Restricted Stock Units | 3,605 | 0.00 | — | 3,605 | D | ↗ |
| 2024-11-02 | Amoroso Michael | Director / Officer | M-Exempt | A | Common Stock | 9,443 | 0.00 | — | 31,549 | D | ↗ |
| 2024-08-22 | Scimeca Dario | Officer | A-Award | A | Restricted Stock Units | 44,723 | 0.00 | — | 44,723 | — | ↗ |
| 2024-08-22 | SMITH J. JEFFERSON | Officer | A-Award | A | Restricted Stock Units | 48,657 | 0.00 | — | 48,657 | — | ↗ |
| 2024-08-22 | Kelly John Alexander | Officer | A-Award | A | Restricted Stock Units | 79,725 | 0.00 | — | 79,725 | — | ↗ |
| 2024-08-22 | Amoroso Michael | Director / Officer | A-Award | A | Restricted Stock Units | 208,263 | 0.00 | — | 208,263 | — | ↗ |
| 2024-06-10 | Scimeca Dario | Officer | S-Sale | D | Common Stock | 93 | 11.79 | 1.1K | 6,721 | — | ↗ |
| 2024-06-10 | SMITH J. JEFFERSON | Officer | S-Sale | D | Common Stock | 50 | 11.79 | 589.50 | 68,559 | — | ↗ |
| 2024-06-07 | Scimeca Dario | Officer | M-Exempt | A | Common Stock | 301 | 0.00 | — | 6,814 | — | ↗ |
| 2024-06-07 | SMITH J. JEFFERSON | Officer | M-Exempt | A | Common Stock | 163 | 0.00 | — | 68,609 | — | ↗ |
| 2024-06-07 | Kelly John Alexander | Officer | M-Exempt | A | Common Stock | 454 | 0.00 | — | 31,468 | — | ↗ |
| 2024-06-04 | Wadsworth Samuel C. | Director | A-Award | A | Restricted Stock Units | 9,826 | 0.00 | — | 9,826 | — | ↗ |
| 2024-06-04 | Pire Shari Lisa | Director | A-Award | A | Restricted Stock Units | 9,826 | 0.00 | — | 9,826 | — | ↗ |
| 2024-06-04 | Germano Geno J | Director | A-Award | A | Restricted Stock Units | 9,826 | 0.00 | — | 9,826 | — | ↗ |
| 2024-06-04 | Frankel Stanley | Director | A-Award | A | Restricted Stock Units | 9,826 | 0.00 | — | 9,826 | — | ↗ |
| 2024-06-04 | Buehler Kevin | Director | A-Award | A | Restricted Stock Units | 9,826 | 0.00 | — | 9,826 | — | ↗ |
| 2024-06-04 | Brown Melinda | Director | A-Award | A | Restricted Stock Units | 9,826 | 0.00 | — | 9,826 | — | ↗ |
| 2024-05-08 | Scimeca Dario | Officer | A-Award | A | Common Stock | 833 | 12.00 | 10.0K | 6,513 | — | ↗ |
| 2024-05-08 | SMITH J. JEFFERSON | Officer | A-Award | A | Common Stock | 833 | 12.00 | 10.0K | 68,446 | — | ↗ |
| 2024-05-08 | Kelly John Alexander | Officer | A-Award | A | Common Stock | 8,334 | 12.00 | 100.0K | 31,014 | — | ↗ |
| 2024-05-08 | Amoroso Michael | Director / Officer | A-Award | A | Common Stock | 8,334 | 12.00 | 100.0K | 22,106 | — | ↗ |
| 2024-05-04 | Wadsworth Samuel C. | Director | M-Exempt | D | Restricted Stock Units | 4,202 | 0.00 | — | 0 | — | ↗ |
| 2024-05-04 | Pire Shari Lisa | Director | M-Exempt | A | Common Stock | 4,202 | 0.00 | — | 4,202 | — | ↗ |
| 2024-05-04 | Germano Geno J | Director | M-Exempt | A | Common Stock | 4,202 | 0.00 | — | 4,202 | — | ↗ |
| 2024-05-04 | Frankel Stanley | Director | M-Exempt | D | Restricted Stock Units | 4,202 | 0.00 | — | 0 | — | ↗ |
| 2024-05-04 | Buehler Kevin | Director | M-Exempt | A | Common Stock | 4,202 | 0.00 | — | 4,392 | — | ↗ |
| 2024-05-04 | Brown Melinda | Director | M-Exempt | D | Restricted Stock Units | 4,202 | 0.00 | — | 0 | — | ↗ |
| 2024-05-02 | Scimeca Dario | Officer | S-Sale | D | Common Stock | 272 | 10.32 | 2.8K | 5,680 | — | ↗ |
| 2024-05-02 | SMITH J. JEFFERSON | Officer | S-Sale | D | Common Stock | 154 | 10.32 | 1.6K | 67,613 | — | ↗ |
| 2024-05-02 | List Alan | Officer | S-Sale | D | Common Stock | 290 | 10.32 | 3.0K | 4,488 | — | ↗ |
| 2024-05-02 | Amoroso Michael | Director / Officer | S-Sale | D | Common Stock | 1,526 | 10.32 | 15.7K | 13,772 | — | ↗ |
| 2024-05-01 | Scimeca Dario | Officer | M-Exempt | A | Common Stock | 918 | 0.00 | — | 5,952 | — | ↗ |
| 2024-05-01 | SMITH J. JEFFERSON | Officer | M-Exempt | D | Restricted Stock Units | 519 | 0.00 | — | 519 | — | ↗ |
| 2024-05-01 | List Alan | Officer | M-Exempt | A | Common Stock | 982 | 0.00 | — | 4,778 | — | ↗ |
| 2024-05-01 | Kelly John Alexander | Officer | M-Exempt | D | Restricted Stock Units | 1,702 | 0.00 | — | 1,702 | — | ↗ |
| 2024-05-01 | Amoroso Michael | Director / Officer | M-Exempt | D | Restricted Stock Units | 3,417 | 0.00 | — | 3,417 | — | ↗ |
| 2024-04-30 | List Alan | Officer | S-Sale | D | Common Stock | 238 | 10.03 | 2.4K | 3,796 | — | ↗ |
| 2024-04-26 | List Alan | Officer | M-Exempt | A | Common Stock | 868 | 0.00 | — | 4,034 | — | ↗ |
| 2024-04-18 | Scimeca Dario | Officer | A-Award | A | Restricted Stock Units | 25,277 | 0.00 | — | 25,277 | — | ↗ |
| 2024-04-18 | SMITH J. JEFFERSON | Officer | A-Award | A | Restricted Stock Units | 31,343 | 0.00 | — | 31,343 | — | ↗ |
| 2024-04-18 | Kelly John Alexander | Officer | A-Award | A | Restricted Stock Units | 41,705 | 0.00 | — | 41,705 | — | ↗ |
| 2024-04-18 | Amoroso Michael | Director / Officer | A-Award | A | Restricted Stock Units | 111,217 | 0.00 | — | 111,217 | — | ↗ |
| 2024-02-29 | SMITH J. JEFFERSON | Officer | A-Award | A | Common Stock | 1,006 | 12.42 | 12.5K | 67,248 | — | ↗ |
| 2024-02-29 | Kelly John Alexander | Officer | A-Award | A | Common Stock | 506 | 18.50 | 9.4K | 20,978 | — | ↗ |
| 2024-01-23 | SMITH J. JEFFERSON | Officer | S-Sale | D | Common Stock | 28,000 | 0.37 | 10.4K | 1,987,269 | — | ↗ |
| 2024-01-22 | Scimeca Dario | Officer | S-Sale | D | Common Stock | 21,287 | 0.36 | 7.7K | 151,028 | — | ↗ |
| 2024-01-22 | List Alan | Officer | S-Sale | D | Common Stock | 21,526 | 0.36 | 7.7K | 94,982 | — | ↗ |
| 2024-01-22 | Amoroso Michael | Director / Officer | S-Sale | D | Common Stock | 137,390 | 0.36 | 49.5K | 356,433 | — | ↗ |
| 2024-01-20 | Scimeca Dario | Officer | M-Exempt | D | Restricted Stock Units | 59,345 | 0.00 | — | 118,655 | — | ↗ |
| 2024-01-20 | SMITH J. JEFFERSON | Officer | M-Exempt | D | Restricted Stock Units | 75,015 | 0.00 | — | 149,985 | — | ↗ |
| 2024-01-20 | List Alan | Officer | M-Exempt | D | Restricted Stock Units | 60,012 | 0.00 | — | 119,988 | — | ↗ |
| 2024-01-20 | Kelly John Alexander | Officer | M-Exempt | D | Restricted Stock Units | 116,690 | 0.00 | — | 233,310 | — | ↗ |
| 2024-01-20 | Amoroso Michael | Director / Officer | M-Exempt | A | Common Stock | 266,720 | 0.00 | — | 493,823 | — | ↗ |
| 2023-11-03 | Scimeca Dario | Officer | S-Sale | D | Common Stock | 16,023 | 0.40 | 6.4K | 112,970 | — | ↗ |
| 2023-11-03 | Amoroso Michael | Director / Officer | S-Sale | D | Common Stock | 125,025 | 0.40 | 50.0K | 227,103 | — | ↗ |
| 2023-11-02 | Scimeca Dario | Officer | M-Exempt | A | Common Stock | 55,077 | 0.00 | — | 128,993 | — | ↗ |
| 2023-11-02 | Kelly John Alexander | Officer | M-Exempt | A | Common Stock | 108,188 | 0.00 | — | 497,479 | — | ↗ |
| 2023-11-02 | Amoroso Michael | Director / Officer | M-Exempt | D | Restricted Stock Units | 283,390 | 0.00 | — | 566,610 | — | ↗ |
| 2023-08-31 | Scimeca Dario | Officer | A-Award | A | Common Stock | 5,443 | 0.39 | 2.1K | 73,916 | — | ↗ |
| 2023-08-31 | SMITH J. JEFFERSON | Officer | A-Award | A | Common Stock | 5,175 | 0.39 | 2.0K | 1,940,254 | — | ↗ |
| 2023-08-31 | Kelly John Alexander | Officer | A-Award | A | Common Stock | 5,951 | 0.39 | 2.3K | 389,291 | — | ↗ |
| 2023-08-18 | Kelly John Alexander | Officer | A-Award | A | Common Stock | 90,000 | 0.48 | 43.2K | 383,340 | — | ↗ |
| 2023-06-08 | Scimeca Dario | Officer | S-Sale | D | Common Stock | 13,361 | 0.75 | 10.0K | 68,473 | — | ↗ |
| 2023-06-07 | Scimeca Dario | Officer | M-Exempt | D | Restricted Stock Units | 22,727 | 0.00 | — | 0 | — | ↗ |
| 2023-06-07 | SMITH J. JEFFERSON | Officer | M-Exempt | D | Restricted Stock Units | 4,872 | 0.00 | — | 4,872 | — | ↗ |
| 2023-06-07 | Kelly John Alexander | Officer | M-Exempt | D | Restricted Stock Units | 34,091 | 0.00 | — | 0 | — | ↗ |
| 2023-06-07 | Barton Shane | Officer | M-Exempt | D | Restricted Stock Units | 6,060 | 0.00 | — | 6,060 | — | ↗ |
| 2023-05-04 | Wadsworth Samuel C. | Director | A-Award | A | Restricted Stock Units | 126,075 | 0.00 | — | 126,075 | — | ↗ |
| 2023-05-04 | Pire Shari Lisa | Director | A-Award | A | Restricted Stock Units | 126,075 | 0.00 | — | 126,075 | — | ↗ |
| 2023-05-04 | Germano Geno J | Director | A-Award | A | Restricted Stock Units | 126,075 | 0.00 | — | 126,075 | — | ↗ |
| 2023-05-04 | Frankel Stanley | Director | A-Award | A | Restricted Stock Units | 126,075 | 0.00 | — | 126,075 | — | ↗ |
| 2023-05-04 | Buehler Kevin | Director | A-Award | A | Restricted Stock Units | 126,075 | 0.00 | — | 126,075 | — | ↗ |
| 2023-05-04 | Brown Melinda | Director | A-Award | A | Restricted Stock Units | 126,075 | 0.00 | — | 126,075 | — | ↗ |
| 2023-04-27 | List Alan | Officer | S-Sale | D | Common Stock | 7,771 | 0.79 | 6.1K | 56,496 | — | ↗ |
| 2023-04-26 | List Alan | Officer | M-Exempt | A | Common Stock | 26,027 | 0.00 | — | 64,267 | — | ↗ |
| 2023-04-11 | Buehler Kevin | Director | M-Exempt | A | Common Stock | 5,701 | 0.00 | — | 5,701 | — | ↗ |
| 2023-03-22 | Amoroso Michael | Director / Officer | S-Sale | D | Common Stock | 46,999 | 0.82 | 38.5K | 68,738 | — | ↗ |
| 2023-03-21 | Amoroso Michael | Director / Officer | M-Exempt | A | Common Stock | 102,535 | 0.00 | — | 115,737 | — | ↗ |
| 2023-03-17 | Kelly John Alexander | Officer | P-Purchase | A | Common Stock | 20,000 | 0.86 | 17.2K | 245,614 | — | ↗ |
| 2023-03-06 | Scimeca Dario | Officer | S-Sale | D | Common Stock | 12,172 | 1.07 | 13.0K | 50,063 | — | ↗ |
| 2023-03-06 | List Alan | Officer | S-Sale | D | Common Stock | 9,473 | 1.07 | 10.1K | 38,240 | — | ↗ |
| 2023-03-03 | Scimeca Dario | Officer | M-Exempt | D | Restricted Stock Units | 27,558 | 0.00 | — | 55,101 | — | ↗ |
| 2023-03-03 | SMITH J. JEFFERSON | Officer | M-Exempt | A | Common Stock | 15,576 | 0.00 | — | 1,930,207 | — | ↗ |
| 2023-03-03 | List Alan | Officer | M-Exempt | A | Restricted Stock Units | 29,453 | 0.00 | — | 58,890 | — | ↗ |
| 2023-03-03 | Kelly John Alexander | Officer | M-Exempt | D | Restricted Stock Units | 51,071 | 0.00 | — | 102,114 | — | ↗ |
| 2023-03-03 | Barton Shane | Officer | M-Exempt | D | Restricted Stock Units | 12,722 | 0.00 | — | 25,439 | — | ↗ |
| 2023-02-28 | Scimeca Dario | Officer | A-Award | A | Common Stock | 2,163 | 0.95 | 2.1K | 34,677 | — | ↗ |
| 2023-02-28 | SMITH J. JEFFERSON | Officer | A-Award | A | Common Stock | 12,157 | 0.95 | 11.5K | 1,914,631 | — | ↗ |
| 2023-02-28 | Kelly John Alexander | Officer | A-Award | A | Common Stock | 11,605 | 0.95 | 11.0K | 174,543 | — | ↗ |
| 2023-01-20 | Scimeca Dario | Officer | A-Award | A | Restricted Stock Units | 178,000 | 0.00 | — | 178,000 | — | ↗ |
| 2023-01-20 | SMITH J. JEFFERSON | Officer | A-Award | A | Restricted Stock Units | 225,000 | 0.00 | — | 225,000 | — | ↗ |
| 2023-01-20 | List Alan | Officer | A-Award | A | Restricted Stock Units | 180,000 | 0.00 | — | 180,000 | — | ↗ |
| 2023-01-20 | Kelly John Alexander | Officer | A-Award | A | Restricted Stock Units | 350,000 | 0.00 | — | 350,000 | — | ↗ |
| 2023-01-20 | Barton Shane | Officer | A-Award | A | Restricted Stock Units | 70,000 | 0.00 | — | 70,000 | — | ↗ |
| 2023-01-20 | Amoroso Michael | Officer | A-Award | A | Restricted Stock Units | 800,000 | 0.00 | — | 800,000 | — | ↗ |
| 2022-11-02 | Scimeca Dario | Officer | A-Award | A | Restricted Stock Units | 165,200 | 0.00 | — | 165,200 | — | ↗ |
| 2022-11-02 | Kelly John Alexander | Officer | A-Award | A | Restricted Stock Units | 324,500 | 0.00 | — | 324,500 | — | ↗ |
| 2022-11-02 | Amoroso Michael | Officer | A-Award | A | Restricted Stock Units | 850,000 | 0.00 | — | 850,000 | — | ↗ |
| 2022-10-24 | Amoroso Michael | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.00 | — | 250,000 | — | ↗ |
| 2022-10-17 | Amoroso Michael | Officer | S-Sale | D | Common Stock | 11,006 | 1.32 | 14.5K | 13,202 | — | ↗ |
| 2022-10-15 | Amoroso Michael | Officer | M-Exempt | A | Common Stock | 24,208 | 0.00 | — | 24,208 | — | ↗ |
| 2022-09-23 | Kelly John Alexander | Officer | P-Purchase | A | Common Stock | 8,200 | 1.23 | 10.1K | 162,938 | — | ↗ |
| 2022-09-22 | Kelly John Alexander | Officer | P-Purchase | A | Common Stock | 37,037 | 1.34 | 49.6K | 154,738 | — | ↗ |
| 2022-09-01 | SMITH J. JEFFERSON | Officer | — | D | Employee Stock Option (Right to Buy) | 23,422 | 1.18 | 27.6K | 0 | — | ↗ |
| 2022-06-22 | Kelly John Alexander | Officer | P-Purchase | A | Common Stock | 33,784 | 1.50 | 50.7K | 117,701 | — | ↗ |
| 2022-06-15 | NOVARTIS PHARMA AG | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 12,407,440 | — | ↗ |
| 2022-06-07 | Scimeca Dario | Officer | M-Exempt | A | Common Stock | 9,047 | 0.00 | — | 42,347 | — | ↗ |
| 2022-06-07 | Kelly John Alexander | Officer | M-Exempt | D | Restricted Stock Units | 13,638 | 0.00 | — | 27,270 | — | ↗ |
| 2022-06-07 | JANTZ DEREK | Officer | M-Exempt | D | Restricted Stock Units | 12,199 | 0.00 | — | 24,391 | — | ↗ |
| 2022-06-07 | Barton Shane | Officer | M-Exempt | D | Restricted Stock Units | 6,061 | 0.00 | — | 12,120 | — | ↗ |
| 2022-05-26 | Brown Melinda | Director | A-Award | A | Stock Option (Right to Buy) | 376,683 | 1.55 | 583.9K | 376,683 | — | ↗ |
| 2022-05-10 | Wadsworth Samuel C. | Director | A-Award | A | Stock Option (Right to Buy) | 156,951 | 0.00 | — | 156,951 | — | ↗ |
| 2022-05-10 | Schinazi Raymond F | Director | A-Award | A | Stock Option (Right to Buy) | 156,951 | 0.00 | — | 156,951 | — | ↗ |
| 2022-05-10 | Pire Shari Lisa | Director | A-Award | A | Stock Option (Right to Buy) | 156,951 | 0.00 | — | 156,951 | — | ↗ |
| 2022-05-10 | Germano Geno J | Director | A-Award | A | Stock Option (Right to Buy) | 156,951 | 0.00 | — | 156,951 | — | ↗ |
| 2022-05-10 | Frankel Stanley | Director | A-Award | A | Stock Option (Right to Buy) | 156,951 | 0.00 | — | 156,951 | — | ↗ |
| 2022-05-10 | Buehler Kevin | Director | A-Award | A | Stock Option (Right to Buy) | 156,951 | 0.00 | — | 156,951 | — | ↗ |
| 2022-04-26 | List Alan | Officer | M-Exempt | D | Restricted Stock Units | 26,035 | 0.00 | — | 52,055 | — | ↗ |
| 2022-04-11 | Buehler Kevin | Director | A-Award | A | Stock Option (Right to Buy) | 8,763 | 2.85 | 25.0K | 8,763 | — | ↗ |
| 2022-03-21 | Amoroso Michael | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 482,771 | 3.05 | 1.47M | 482,771 | — | ↗ |
| 2022-03-17 | Kelly John Alexander | Officer | P-Purchase | A | Common Stock | 16,677 | 3.08 | 51.4K | 36,189 | — | ↗ |
| 2022-03-03 | Scimeca Dario | Officer | A-Award | A | Restricted Stock Units | 82,659 | 0.00 | — | 82,659 | — | ↗ |
| 2022-03-03 | List Alan | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 140,299 | 0.00 | — | 140,299 | — | ↗ |
| 2022-03-03 | Kelly John Alexander | Officer | A-Award | A | Restricted Stock Units | 153,185 | 0.00 | — | 153,185 | — | ↗ |
| 2022-03-03 | JANTZ DEREK | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 156,271 | 4.08 | 637.6K | 156,271 | — | ↗ |
| 2022-03-03 | Barton Shane | Officer | A-Award | A | Restricted Stock Units | 38,161 | 0.00 | — | 38,161 | — | ↗ |
| 2022-02-28 | Scimeca Dario | Officer | A-Award | A | Common Stock | 2,049 | 3.61 | 7.4K | 10,573 | — | ↗ |
| 2022-02-28 | Kelly John Alexander | Officer | A-Award | A | Common Stock | 2,714 | 3.61 | 9.8K | 19,512 | — | ↗ |
| 2022-02-28 | Barton Shane | Officer | A-Award | A | Common Stock | 761 | 3.61 | 2.7K | 2,659 | — | ↗ |
| 2022-02-22 | JANTZ DEREK | Director / Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 21,514 | 0.04 | 860.56 | 193,626 | — | ↗ |
| 2021-11-08 | Wadsworth Samuel C. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-482.9K
Shares Outstanding
12.83M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Michael Amoroso President, Chief Executive Officer and Director | 650.9K | 451.3K | 1.03M | — | — | 62.2K | 2.19M | 46.82% | ↗ |
| 2 | 2025 | Alex Kelly Chief Financial Officer | 472.5K | 222.2K | 417.1K | — | — | 22.3K | 1.13M | 36.77% | ↗ |
| 3 | 2025 | Dario Scimeca General Counsel and Secretary | 445.9K | 193.6K | 252.0K | — | — | 20.2K | 911.6K | 27.64% | ↗ |
| 4 | 2024 | Michael Amoroso President, Chief Executive Officer and Director | 635.0K | 400.1K | 3.22M | — | — | 59.3K | 4.31M | 74.61% | ↗ |
| 5 | 2024 | Alex Kelly Chief Financial Officer | 461.0K | 191.8K | 1.22M | — | — | 18.6K | 1.89M | 64.54% | ↗ |
| 6 | 2024 | Jeff Smith, Ph.D. Chief Research Officer | 400.0K | 230.6K | 808.9K | — | — | 9.6K | 1.45M | 55.82% | ↗ |
| 7 | 2023 | Michael Amoroso President, Chief Executive Officer and Director | 629.9K | 381.0K | 968.0K | — | — | 60.4K | 2.04M | 47.47% | ↗ |
| 8 | 2023 | Alex Kelly Chief Financial Officer | 457.7K | 184.4K | 423.5K | — | — | 18.8K | 1.08M | 39.05% | ↗ |
| 9 | 2023 | Alan List, M.D. Chief Medical Officer | 475.7K | 191.2K | 217.8K | — | — | 25.3K | 910.0K | 23.93% | ↗ |
| 10 | 2022 | Michael Amoroso President, Chief Executive Officer and Director | 603.6K | 351.8K | 2.12M | 1.27M | — | 23.7K | 4.37M | 77.59% | ↗ |
| 11 | 2022 | Alex Kelly Chief Financial Officer | 437.5K | 173.9K | 1.08M | 679.2K | — | 12.1K | 2.38M | 73.79% | ↗ |
| 12 | 2022 | Dario Scimeca General Counsel and Secretary | 409.0K | 160.5K | 566.9K | 366.5K | — | 7.0K | 1.51M | 61.82% | ↗ |
| 13 | 2021 | Michael Amoroso President, Chief Executive Officer and Director | 127.3K | 275.0K | 237.0K | 5.35M | — | — | 5.98M | 93.28% | ↗ |
| 14 | 2021 | Alex Kelly Chief Financial Officer | 420.0K | 144.7K | 1.24M | 1.39M | — | 126.4K | 3.32M | 79.18% | ↗ |
| 15 | 2021 | Derek Jantz, Ph.D. Chief Scientific Officer and Director | 445.0K | 140.3K | 1.09M | 1.22M | — | 12.1K | 2.90M | 79.42% | ↗ |
| 16 | 2021 | Matthew Kane Former President, Chief Executive Officer and Director | 444.4K | 146.9K | — | — | — | 266.5K | 857.8K | 0.00% | ↗ |
| 17 | 2020 | Matthew Kane President and Chief Executive Officer | 523.0K | 198.7K | — | 1.10M | — | 11.8K | 1.84M | 60.06% | ↗ |
| 18 | 2020 | Matthew Kane Former President, Chief Executive Officer and Director | 523.0K | 198.7K | — | 1.10M | — | 11.8K | 1.84M | 60.06% | ↗ |
| 19 | 2020 | David Thomson, Ph.D. Chief Operating Officer | 415.0K | 145.3K | — | 844.2K | — | 11.6K | 1.42M | 59.62% | ↗ |
| 20 | 2020 | Christopher Heery, M.D. Chief Medical Officer | 430.0K | 146.2K | — | 726.0K | — | 11.2K | 1.31M | 55.28% | ↗ |
| 21 | 2019 | Christopher Heery, M.D. Chief Medical Officer | 286.7K | 150.5K | — | 1.74M | — | 6.8K | 2.18M | 79.65% | ↗ |
| 22 | 2019 | Christopher Heery Chief Medical Officer | 286.7K | 150.5K | — | 1.74M | — | 6.8K | 2.18M | 79.65% | ↗ |
| 23 | 2019 | Matthew Kane President and Chief Executive Officer | 479.8K | 68.0K | — | 1.60M | — | 14.4K | 2.17M | 74.05% | ↗ |
| 24 | 2019 | Matthew Kane President and Chief Executive Officer | 479.8K | 68.0K | — | 1.60M | — | 14.4K | 2.17M | 74.05% | ↗ |
| 25 | 2019 | Dario Scimeca General Counsel | 174.4K | 80.1K | — | 1.39M | — | 65.5K | 1.71M | 81.29% | ↗ |
| 26 | 2019 | David Thomson, Ph.D. Chief Operating Officer | 383.6K | 149.4K | — | 189.2K | — | 12.2K | 734.4K | 25.76% | ↗ |
| 27 | 2018 | Matthew Kane President and Chief Executive Officer | 350.0K | 157.5K | — | 1.07M | — | 11.0K | 1.59M | 67.33% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael Amoroso | President, Chief Executive Officer & Director | 1M | male |
| John Alexander Kelly | Chief Financial Officer & Principal Accounting Officer | 717.1K | male |
| Dario Scimeca | General Counsel & Secretary | 659.6K | male |
| Jefferson J. Smith | Co-Founder & Chief Research Officer | 640.2K | — |
| Cassie Gorsuch | Chief Scientific Officer | — | — |
| Neil Leatherbury | Senior Vice President and Head of Chemistry, Manufacturing & Controls | — | male |
| Cindy Atwell | Chief Development & Business Officer | — | female |
| Juli Blanche | Chief People Officer | — | female |
| Naresh Tanna | Chief of Staff to Chief Executive Officer & Head of Investor Relations | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DTIL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
